Libtayo 350 mg/7 mL (50 mg/mL) injection Images
Generic Name: cemiplimab
This medication has been identified as Libtayo 350 mg/7 mL (50 mg/mL) injection and is used for Squamous Cell Carcinoma, Non Small Cell Lung Cancer, and Basal Cell Carcinoma. It belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) and is not a controlled substance.
Images of medication
Libtayo
- Generic Name
- cemiplimab
- Strength
- 350 mg/7 mL (50 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Regeneron Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 61755-0008
See also:
More about Libtayo (cemiplimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (9)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.